EWA
NRIX icon

EverSource Wealth Advisors’s Nurix Therapeutics NRIX Stock Holding History

EverSource Wealth Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155 Buy
+10
New +$166 ﹤0.01% 4228
2025
Q3 		– Sell
-129
Closed -$1.47K – 4428
2025
Q2 		$1.47K Buy
+129
New +$1.39K ﹤0.01% 3609
2025
Q1 		– Sell
-33
Closed -$622 – 4126
2024
Q4 		$622 Buy
+33
New +$756 ﹤0.01% 3116

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

EverSource Wealth Advisors's NRIX Position: Q1 2026 in Review

EverSource Wealth Advisors opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 10 shares worth $155. The stake represents ﹤0.01% of the portfolio and ranks #4228 among its holdings. This is a return to the name: EverSource Wealth Advisors previously reported a position in NRIX as recently as Q2 2025.

EverSource Wealth Advisors first reported a position in NRIX in Q4 2024 and has held it in 3 quarters since. The position peaked at $1.47K in Q2 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • EverSource Wealth Advisors held 10 shares of Nurix Therapeutics worth $155 as of Q1 2026.
  • Nurix Therapeutics was a new EverSource Wealth Advisors position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4228 holding.
  • EverSource Wealth Advisors first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • EverSource Wealth Advisors's Nurix Therapeutics position peaked at $1.47K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.